Evidence map›Paper›PMID 28815345›Full record

ArticleDigestive diseases and sciences2017

Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CCl

Hong Xu, Jingfang Xiong, Jianjun Xu, Shuiming Li, Yang Zhou, Dongya Chen, Xinjun Cai, Jian Ping, Min Deng, Jianyong Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Hong XuDepartment of Gastroenterology and Hepatology, Hangzhou Red Cross Hospital, 208 Huancheng Dong Road, Hangzhou, 310003, China.
Jingfang XiongDepartment of Geriatrics, Hangzhou Red Cross Hospital, Hangzhou, China.
Jianjun XuDepartment of Gastroenterology and Hepatology, Hangzhou Red Cross Hospital, 208 Huancheng Dong Road, Hangzhou, 310003, China.
Shuiming LiKey Laboratory of Marine Bioresources and Ecology, College of Life Science, Shenzhen University, Shenzhen, China.
Yang ZhouLiver Cirrhosis Section, Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Dongya ChenDepartment of Gastroenterology and Hepatology, Hangzhou Red Cross Hospital, 208 Huancheng Dong Road, Hangzhou, 310003, China.
Xinjun CaiDepartment of Pharmacy, Hangzhou Red Cross Hospital, Hangzhou, China.
Jian PingLiver Cirrhosis Section, Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Min DengDepartment of Emergency, Hangzhou Red Cross Hospital, 208 Huancheng Dong Road, Hangzhou, 310003, China. dengmindoctor@aliyun.com.
Jianyong ChenDepartment of Gastroenterology and Hepatology, Hangzhou Red Cross Hospital, 208 Huancheng Dong Road, Hangzhou, 310003, China. chenjy@medmail.com.cn.
Hangzhou Red Cross Hospital · CNShuguang Hospital · CNShenzhen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImpaired intestinal motility may lead to the disruption of gut microbiota equilibrium, which in turn facilitates bacterial translocation (BT) and endotoxemia in cirrhosis. We evaluated the influence of mosapride, a prokinetic agent, on BT and DNA fingerprints of gut microbiota in cirrhotic rats.

methodsA rat model of cirrhosis was set up via subcutaneous injection of carbon tetrachloride (CCl

resultsMosapride treatment to cirrhotic rats significantly reduced the plasma endotoxin level and incidence of BT, accompanied by increased ITR. Cirrhotic rats (including those treated with mosapride) suffered from BT exhibited significantly lower ITR than those who are free of BT. Pearson coefficient indicated a significant and negative correlation between the plasma endotoxin level and ITR. The genomic fingerprints of intestinal microbiota from the three groups fell into three distinctive clusters. In the mosapride-treated group, Shannon's index was remarkably increased compared to the model group. Significantly positive correlation was detected between Shannon's index and ITR. Mosapride did not improve hepatic and intestinal damages and ileal expressions of occludin and ZO-1.

conclusionsMosapride significantly increases intestinal motility in cirrhotic rats, thus to recover the disordered intestinal microbiota, finally resulting in decreased plasma endotoxin and BT.

Indexed as

Carbon TetrachlorideAnimalsBacterial TranslocationBenzamidesChemical and Drug Induced Liver InjuryDNA, BacterialEndotoxemiaFecesGastrointestinal AgentsGastrointestinal MicrobiomeGastrointestinal MotilityIntestinal MucosaIntestinesLiverLiver Cirrhosis, ExperimentalMaleBenzamidesCarbon TetrachlorideDNA, BacterialGastrointestinal AgentsMorpholinesmosaprideTight Junction ProteinsBacterial translocationEnterobacterial repetitive intergenic consensusIntestinal microbiotaLiver cirrhosisMosapride

Identifiers

PMID28815345
OpenAlexW2747467983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.